Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.
Lead Product(s): ACI-24.060
Therapeutic Area: Neurology Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Worldwide Clinical Trials
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, and thereby may reduce or prevent disease progression.
Lead Product(s): ACI-24.060
Therapeutic Area: Neurology Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
Early clinical testing showed that ACI-35.030, a first-in-class anti-pTau vaccine, was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and ePHF species, both of which are closely implicated in AD.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030, a first-in-class tau vaccine candidate in participants with early Alzheimer’s disease treatment.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
The ACI-35.030 anti-pTau vaccine is the second vaccine under investigation generated from AC Immune’s SupraAntigen™ platform, along with ACI-24, a proprietary anti-amyloid beta (Abeta) vaccine currently in Phase 1b/Phase 2 clinical development in two separate indications.
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020